logo.png
Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topical Wound Treatment
March 24, 2021 08:25 ET | Arch Biopartners
TORONTO, March 24, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has entered into an exclusive agreement with the...
Veteran-Owned Healthcare Company Awarded $43 Million Contract to Aide Department of Defense (DOD) and Federal Agencies
April 07, 2020 08:41 ET | Alliant Healthcare
Michigan, April 07, 2020 (GLOBE NEWSWIRE) -- Michigan-based Alliant Healthcare Products has been awarded a Laboratory ECAT contract by the Defense Logistics Agency valued at $43,750,000 over 5 years....
logo.png
Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance
March 27, 2018 09:08 ET | Arch Biopartners
TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that the U.S. Patent and Trademark Office has issued U.S....